Plus Therapeutics (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.
The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.
The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.
Price: 1.45, Change: +0.93, Percent Change: +182.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。